Circulating biomarkers for monitoring therapy response and detection of disease progression in lung cancer patients
Remco de Kock, Ben van den Borne, Maggy Youssef-El Soud, Huub Belderbos, Gerben Stege, Marleen de Saegher, Claartje van Dongen-Schrover, Sylvia Genet, Luc Brunsveld, Volkher Scharnhorst, Birgit Deiman, Remco de Kock, Ben van den Borne, Maggy Youssef-El Soud, Huub Belderbos, Gerben Stege, Marleen de Saegher, Claartje van Dongen-Schrover, Sylvia Genet, Luc Brunsveld, Volkher Scharnhorst, Birgit Deiman
Abstract
Liquid biopsies have become of interest as minimally invasive ways to monitor treatment response in lung cancer patients. Circulating tumor DNA (ctDNA) and protein biomarkers are evaluated for their added value in monitoring therapy response and early detection of disease progression. Plasma and serum samples of non-small cell or small cell lung cancer patients were analyzed for driver mutations in ctDNA (EGFR, KRAS or BRAF) using droplet digital PCR and protein biomarkers (CA125, CEA, CA15.3, Cyfra 21-1, HE4, NSE, proGRP and SCCA) using electrochemiluminescence immunoassays. Biomarker concentration changes were compared with the outcome of CT-scans during therapy. The median difference of the concentration of ctDNA, CA125 and Cyfra21-1 was significantly lower in patients with partial response (PR) compared to patients with progressive disease (PD) on the first evaluation CT-scan (P<0.001, P=0.042 and P=0.020, respectively). A substantial agreement between ctDNA or CA125 response and radiographic response was observed (k=0.692 and k=0.792, respectively). The median difference of the concentration of ctDNA and Cyfra21-1 was also significantly lower in PR patients compared to PD patients at the last CT-scan during therapy (P<0.001 and P=0.026, respectively). An almost perfect agreement between ctDNA and radiographic response (k=0.827) and a moderate agreement between Cyfra21-1 response and radiographic response was observed (k=0.553). Serial testing of the concentration of ctDNA, Cyfra21-1, and possibly CA125 could be a useful added tool for monitoring therapy response and early detection of disease progression in lung cancer patients.
Keywords: Circulating tumor DNA; Early detection disease progression; Liquid Biopsy; NSCLC; Protein tumor markers; Therapy response monitoring.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Source: PubMed